Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 17/20 | 1.00 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049856 | 1.00 | OTUD7B (1.00) | OTUD7BUSP30 | |
| SCHEMBL19031226 | 0.90 | OTUD7B (1.00) | OTUD7BUSP30 | |
| SCHEMBL19049845 | 0.88 | OTUD7B (1.00) | OTUD7BUSP30 | |
| SCHEMBL19031337 | 0.88 | OTUD7B (1.00) | OTUD7BUSP30 | |
| SCHEMBL19049731 | 0.85 | OTUD7B (0.80) | OTUD7BUSP30 | |
| SCHEMBL19031447 | 0.84 | OTUD7B (1.00) | OTUD7BUSP30 | |
| SCHEMBL23198240 | 0.83 | USP30 (1.00) | OTUD7BUSP30 | |
| SCHEMBL19031531 | 0.81 | OTUD7B (1.00) | OTUD7BUSP30 | |
| SCHEMBL17631989 | 0.78 | UCHL1 (0.77) | OTUD7BUSP30 | |
| SCHEMBL17631985 | 0.78 | UCHL1 (0.77) | OTUD7BUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394049-B1 | CYANOPYRROLIDINE DERVIVATIVES AS INHBITORS FOR DUBS | MISSION THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | claimed |
| CN-108290872-B | Cyanopyrrolidine derivatives as DUBs inhibitors | 特殊治疗有限公司 | 2020-10-02 | — | — | CN | claimed |
| US-10590075-B2 | Cyanopyrrolidine derivatives as inhibitors for DUBs | MISSION THERAPEUTICS LIMITED (GB) | 2020-03-17 | — | — | US | claimed |
| US-20180362460-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2018-12-20 | — | — | US | claimed |
| EP-3394049-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | Mission Therapeutics Limited (GB) | 2018-10-31 | — | — | EP | claimed |
| WO-2017109488-A1 | CYANOPYRROLIDINE DERVIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-29 | — | — | WO | claimed |
| EP-3394049-B1 | CYANOPYRROLIDINE DERVIVATIVES AS INHBITORS FOR DUBS | MISSION THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3394049-B1 | CYANOPYRROLIDINE DERVIVATIVES AS INHBITORS FOR DUBS | MISSION THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-108290872-B | Cyanopyrrolidine derivatives as DUBs inhibitors | 特殊治疗有限公司 | 2020-10-02 | — | — | CN | disclosed |
| US-10590075-B2 | Cyanopyrrolidine derivatives as inhibitors for DUBs | MISSION THERAPEUTICS LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-10590075-B2 | Cyanopyrrolidine derivatives as inhibitors for DUBs | MISSION THERAPEUTICS LIMITED (GB) | 2020-03-17 | — | — | US | disclosed |
| US-20180362460-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| EP-3394049-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | Mission Therapeutics Limited (GB) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017109488-A1 | CYANOPYRROLIDINE DERVIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017109488-A1 | CYANOPYRROLIDINE DERVIVATIVES AS INHIBITORS FOR DUBS | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590075-B2 | Cyanopyrrolidine derivatives as inhibitors for DUBs | USP30, USP1, USP39 | OTUD7B 165/4885USP30 1/4885 |
| US-20180362460-A1 | CYANOPYRROLIDINE DERIVATIVES AS INHIBITORS FOR DUBS | USP30, USP1, USP39 | OTUD7B 165/4885USP30 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.